2PIQ

androgen receptor LBD with small molecule

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 0.250 
  • R-Value Work: 0.210 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history. 


Literature

A surface on the androgen receptor that allosterically regulates coactivator binding.

Estebanez-Perpina, E., Arnold, L.A., Arnold, A.A., Nguyen, P., Rodrigues, E.D., Mar, E., Bateman, R., Pallai, P., Shokat, K.M., Baxter, J.D., Guy, R.K., Webb, P., Fletterick, R.J.

(2007) Proc Natl Acad Sci U S A 104: 16074-16079

  • DOI: 10.1073/pnas.0708036104
  • Primary Citation of Related Structures:  
    2QPY, 2PIR, 2PIQ, 2PIP, 2PIO, 2PIX, 2PIW, 2PIV, 2PIU, 2PIT

  • PubMed Abstract: 

    • Current approaches to inhibit nuclear receptor (NR) activity target the hormone binding pocket but face limitations. We have proposed that inhibitors, which bind to nuclear receptor surfaces that mediate assembly of the receptor's binding partners, might overcome some of these limitations ...

    Current approaches to inhibit nuclear receptor (NR) activity target the hormone binding pocket but face limitations. We have proposed that inhibitors, which bind to nuclear receptor surfaces that mediate assembly of the receptor's binding partners, might overcome some of these limitations. The androgen receptor (AR) plays a central role in prostate cancer, but conventional inhibitors lose effectiveness as cancer treatments because anti-androgen resistance usually develops. We conducted functional and x-ray screens to identify compounds that bind the AR surface and block binding of coactivators for AR activation function 2 (AF-2). Four compounds that block coactivator binding in solution with IC(50) approximately 50 microM and inhibit AF-2 activity in cells were detected: three nonsteroidal antiinflammatory drugs and the thyroid hormone 3,3',5-triiodothyroacetic acid. Although visualization of compounds at the AR surface reveals weak binding at AF-2, the most potent inhibitors bind preferentially to a previously unknown regulatory surface cleft termed binding function (BF)-3, which is a known target for mutations in prostate cancer and androgen insensitivity syndrome. X-ray structural analysis reveals that 3,3',5-triiodothyroacetic acid binding to BF-3 remodels the adjacent interaction site AF-2 to weaken coactivator binding. Mutation of residues that form BF-3 inhibits AR function and AR AF-2 activity. We propose that BF-3 is a previously unrecognized allosteric regulatory site needed for AR activity in vivo and a possible pharmaceutical target.

    Organizational Affiliation: 

    Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94143, USA.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Androgen receptorA251Homo sapiensMutation(s): 0 
Gene Names: AR, DHTR, NR3C4
Find proteins for P10275 (Homo sapiens)
Explore P10275 
Go to UniProtKB:  P10275
NIH Common Fund Data Resources
PHAROS:  P10275
GTEx:  ENSG00000169083
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
RB1
Query on RB1
Download Ideal Coordinates CCD File 
 D [auth A]3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
C16 H19 N5 O
QMAIQPBRCNEJAT-UHFFFAOYSA-N		 Ligand Interaction
DHT
Query on DHT
Download Ideal Coordinates CCD File 
 C [auth A]5-ALPHA-DIHYDROTESTOSTERONE
C19 H30 O2
NVKAWKQGWWIWPM-ABEVXSGRSA-N		 Ligand Interaction
SO4
Query on SO4
Download Ideal Coordinates CCD File 
 B [auth A]SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L		 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
DHTKi:  10   nM  BindingDB
DHTKi:  0.27000001072883606   nM  BindingDB
DHTKi:  0.8999999761581421   nM  BindingDB
DHTKi:  0.6899999976158142   nM  BindingDB
DHTEC50:  0.9700000286102295   nM  BindingDB
DHTEC50:  20   nM  BindingDB
DHTKi:  0.30000001192092896   nM  BindingDB
DHTEC50:  1   nM  BindingDB
DHTKi:  0.20000000298023224   nM  BindingDB
DHTEC50:  5.699999809265137   nM  BindingDB
DHTEC50:  6.199999809265137   nM  BindingDB
DHTEC50:  3.9800000190734863   nM  BindingDB
DHTKi:  0.2800000011920929   nM  BindingDB
DHTKi:  4.699999809265137   nM  BindingDB
DHTIC50:  0   nM  BindingDB
DHTKi:  3   nM  BindingDB
DHTEC50:  2.799999952316284   nM  BindingDB
DHTEC50:  6   nM  BindingDB
DHTEC50:  5   nM  BindingDB
DHTKi:  2   nM  BindingDB
DHTEC50:  0.18000000715255737   nM  BindingDB
DHTEC50:  3   nM  BindingDB
DHTEC50:  5.099999904632568   nM  BindingDB
DHTKi:  0.4300000071525574   nM  BindingDB
DHTEC50:  2   nM  BindingDB
DHTEC50:  0.05000000074505806   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 0.250 
  • R-Value Work: 0.210 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 56.64α = 90
b = 66.25β = 90
c = 71.87γ = 90
Software Package:
Software NamePurpose
ELVESrefinement
CNSrefinement
ELVESdata reduction
ELVESdata scaling
CNSphasing

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2007-09-25
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2017-10-18
    Changes: Refinement description